Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology is viewed favorably because ziftomenib is showing strong, durable activity across AML settings, with KOMET-007 in 99 frontline patients delivering 96% CRc in NPM1m and 90% in KMT2A-r, 12-month OS of 94% and 71%, and central MRD-negativity in 79% and 56% of responders. Its safety profile also appears highly differentiated, with only three Grade 3 QTc cases not judged ziftomenib-related, low differentiation syndrome, and no additive myelosuppression, supporting broad combinability with 7+3, ven/aza, and FLT3 inhibitors. Financially, KOMZIFTI revenues reached $9.1M, up 57% sequentially, new patient starts rose 35% to 115, prescriptions increased 59% to 250+, and the company held $580.8MM in cash, while the broader frontline opportunity could expand toward a ~$7B TAM.

Kura Oncology is viewed negatively because its 2Q26 results still point to a business that remains highly dependent on a narrow clinical pipeline, with $20.9MM in revenue, $9.1MM from KOMZIFTI sales, and a $68.3MM net loss, or ($0.77)/share. Despite $519MM in cash and $180MM in anticipated collaboration payments, the company faces meaningful funding needs, and its value depends heavily on ziftomenib and tipifarnib succeeding in indications where efficacy, safety, biomarker selection, and regulatory approval remain uncertain. Competitive pressure from larger oncology players, plus the risk that sales may miss expectations or that development delays force additional equity financing, creates substantial dilution and execution risk.